To compare the efficacy of tenofovir propofol and entecavir in the treatment of chronic hepatitis B(CHB) and their effects on serum Golgi protein(GP)73 and hepatitis B virus(HBV)-RNA.
A total of 96 eligible CHB patients admitted to our hospital from September 2023 to January 2025 were selected and randomly divided into the observation group and the control group, with 48 cases in each group. The control group was treated with entecavir dispersible tablets, while the observation group was treated with tenofovir profol fumarate tablets. Both groups were treated for 28 weeks. The clinical efficacy, GP73, HBV-RNA, hepatitis B surface antigen, HBV-DNA levels, liver function, liver fibrosis and the occurrence of adverse reactions were compared between the two groups.
After treatment, there was a statistically significant difference in the total effective rate between the two groups(P<0.05). After treatment, the levels of GP73, HBV-RNA, hepatitis B surface antigen, HBV-DNA, alanine transaminase, aspartate transaminase, total bilirubin, laminin, procollagen type Ⅲ, type Ⅳ collagen, hyaluronic acid in the observation group were lower than those in the control group(P<0.05). There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).
Tenofovir propofol can effectively improve liver function in patients with CHB, has good safety, and has a good antiviral effect when used for a long time.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |